The compound’s IC50 value for AChE inhibition (2.64 ± 0.08 μM) and moderate activity against BuChE (IC50 = 55.58 ± 1.41 μM) suggest that it may be particularly effective in modulating cholinergic dysfunctions associated with AD. The gene discussed is ACHE; the disease is Alzheimer disease.